NCT02928367: ELDER-BIOME

The Effect of Leukocyte Dna mEthylation and micRoBIOME Diversity on Host Defense Mechanisms During Community-acquired Pneumonia (ELDER-BIOME)

Status unknown Last updated 9 January 2020

What this trial tests

trial testing rectal swab in Pneumonia in 231 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	231
Start date	1 October 2016
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across Netherlands

Drugs / interventions tested

• rectal swab — full drug profile →
• nasopharyngeal swab — full drug profile →
• blood draw — full drug profile →

Conditions studied

• Pneumonia — all drugs for Pneumonia →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Community-acquired pneumonia (CAP) represents a major health care problem and mortality and morbidity associated with severe pneumonia remain considerable, despite state of the art care.

While the role of altered DNA methylation in cancer has been widely studied, knowledge of its impact on antibacterial defense is highly limited. In addition, recent preclinical studies showed that the gut and respiratory microbiota contributes to host defense against bacterial pneumonia.

This study aims to explore a completely novel research area linking the extent of DNA methylation in blood leukocyte (monocytes and neutrophils) and function of gut and respiratory microbiota on the influence of innate immune responses to and host defense against CAP

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Disruptions of Anaerobic Gut Bacteria Are Associated with Stroke and Post-stroke Infection: a Prospective Case-Control Study.
   Haak BW, Westendorp WF, van Engelen TSR, Brands X, et al · · 2021 · cited 104× · PMID 33052545 · DOI 10.1007/s12975-020-00863-4
2. Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19.
   Saris A, Reijnders TDY, Nossent EJ, Schuurman AR, et al · · 2021 · cited 60× · PMID 33846275 · DOI 10.1136/thoraxjnl-2020-216256
3. Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia.
   Brands X, Haak BW, Klarenbeek AM, Otto NA, et al · · 2020 · cited 30× · PMID 32477337 · DOI 10.3389/fimmu.2020.00796
4. The host response in different aetiologies of community-acquired pneumonia.
   Schuurman AR, Reijnders TDY, van Engelen TSR, Léopold V, et al · · 2022 · cited 26× · PMID 35660785 · DOI 10.1016/j.ebiom.2022.104082
5. The Platelet Lipidome Is Altered in Patients with COVID-19 and Correlates with Platelet Reactivity.
   Schuurman AR, Léopold V, Pereverzeva L, Chouchane O, et al · · 2022 · cited 25× · PMID 35850149 · DOI 10.1055/s-0042-1749438
6. An epigenetic and transcriptomic signature of immune tolerance in human monocytes through multi-omics integration.
   Brands X, Haak BW, Klarenbeek AM, Butler J, et al · · 2021 · cited 22× · PMID 34399830 · DOI 10.1186/s13073-021-00948-1
7. Integrated single-cell analysis unveils diverging immune features of COVID-19, influenza, and other community-acquired pneumonia.
   Schuurman AR, Reijnders TDY, Saris A, Ramirez Moral I, et al · · 2021 · cited 15× · PMID 34424199 · DOI 10.7554/elife.69661
8. Age-related changes in plasma biomarkers and their association with mortality in COVID-19.
   Michels EHA, Appelman B, de Brabander J, van Amstel RBE, et al · · 2023 · cited 13× · PMID 37080568 · DOI 10.1183/13993003.00011-2023